Abstract: The invention relates to antibodies, which bind a peptide having a sequence selected from SEQ ID NO: 2, or a fragment or derivative of such an antibody having essentially the same antigen specificity. In particular, the antibodies suited to be used to detect, manage or monitor cancer in a subject, particularly cancer with interleukin-4 induced gene 1 (IL4I1) expressing cells. The invention also relates to kits or devices containing said antibodies, suitable for immunologic detection or reaction from any biological sample.

Abstract: SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. The inventors produced an antibody that is directed against a surface antigen (i.e. CD40) of an antigen presenting cell (i.e. dendritic cell) wherein the heavy chain was conjugated to the receptor-binding domain of the Sars-Cov-2 spike protein for its use as vaccine. In particular, the inventors show that said vaccine induces circulating Ab-secreting hu-B cells, elicits S-specific IgG+ hu-B cells, elicits the expansion of central memory CD4+ hu-T cells and the emergence of effector memory CD4+ T cells, elicits the expansion of central memory CD8+ hu-T cells at and the emergence of effector memory CD8+ T cells at and finally induces Stem-cell like memory hu-CD8+ T cells.

Abstract: Novel anti-human CD25 antibodies or antigen-binding fragments thereof and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or antigen-binding fragment thereof.

Abstract: Novel anti-human CD25 antibodies and their use for treating cancer and infectious diseases. Also, a nucleic acid encoding an anti-human CD25 antibody or an antigen-binding fragment thereof, and a fusion protein including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof. Further, a pharmaceutical composition including an isolated anti-human CD25 antibody or an antigen-binding fragment thereof.

Abstract: A sensor for the continuous in-situ analysis of an aerosol flow for measuring the mass of the micron/submicron particles suspended in the air flow, including an aeraulic sorter allowing the particles to be sorted according to their size with an impactor body with a cascade of one or more stages; at least one MEMS microbalance per stage, with an oscillating silicon membrane located on the impaction zone of the particles; processor connected to each MEMS microbalance to determine the mass of all the particles on the impaction zone; a system for cleaning the MEMS microbalances allowing the evacuation of the particles from the MEMS microbalances; means for driving the aerosol flow.

Abstract: A nickel-based superalloy includes, in atomic percentages, 13% to 21% chromium, 15% to 26% cobalt, 4% to 8% aluminum, 4.5% to 8% titanium, 8% to 18% iron, boron in an atomic percentage less than or equal to 0.5% or no boron, carbon in an atomic percentage less than or equal to 1% or no carbon, at least one additional element selected from molybdenum, tungsten, tantalum and niobium, a total atomic content of the at least one additional element being less than or equal to 1.5% or no such at least one additional element, the remainder being nickel and unavoidable impurities, with a sum of the atomic percentages of aluminum and titanium being comprised between 8.5% and 15%. The novel superalloy composition has a limited density and exhibiting, when hot, good mechanical properties as well as good resistance to oxidation and corrosion.

Abstract: The present disclosure provides polypeptides derived from SARS-CoV-2 which have therapeutic use. One such polypeptide is a polypeptide, referred to as “Npep2,” is derived from the SARS-CoV-2 protein N and has at least 50 consecutive amino acids of the amino acid sequence having at least 90% identity with the amino acid sequence that ranges from the residue at position 276 to the residue at position 411 of SEQ ID NO:2. Further described are conjugates wherein a heterologous polypeptide is conjugated or fused to Npep2. The present disclosure further provides vaccines employing the polypeptides, polynucleotides encoding the polypeptides, and methods of vaccinating subjects against SARS-CoV-2 by administering a therapeutically effective amount of one or more of the polypeptides.

Abstract: The invention relates to a compound of the formula Li7-xPS6-xXx-z(BH4)z, in which x is selected from the group comprising Cl, Br, I, F and CN, 0?x?2, 0?z?0.50. This compound can be used as a solid electrolyte of a lithium-ion electrochemical element.

Abstract: The aim of the present invention is to propose a novel method for spectral study of a biological fluid from an absorption spectrum of a sample of the biological fluid. The inventors have made an original use of spectroscopy in order to accurately determine the protein content of a biological sample, in particular for oxyhaemoglobin, methaemoglobin, bilirubin and the haem bound to serum albumin. Such a method can be used in a variety of applications concerning haem- or haemoprotein- related diseases, in particular diagnostic methods, treatment follow-up methods, methods for determining biomarkers or screening methods. Such a method is also advantageous for qualifying blood bags.

Abstract: Novel anti-CD25 antibodies and antigen-bind fragments thereof that do not inhibit the binding of interleukin-2 (IL-2) to CD25, and the use thereof for treating cancer or an infectious disease. Also, fusion proteins including the antibodies and antigen-bind fragments, nucleic acids encoding the antibodies and antigen-bind fragments, and an expression vectors including the nucleic acids. Further, pharmaceutical compositions including the fusion proteins or the antibodies and antigen-bind fragments.

Abstract: A portable device (1) for quantifying movements of pronation and/or supination of a person, and intended to be used when the person has the elbow on a horizontal support, comprising: a solid armature (2) with: means for attaching (4), configured to secure one hand of the person in the device (1); a central pivot element (5) intended to be in contact with the horizontal support, during the angular oscillations of the hand, between two opposed identical “first block angles” relative to a vertical position called “neutral position”, the “first block angles” defining a “small amplitude”, first means for blocking (8) the movement of pronation and the movement of supination of the elbow, at the two “first block angles”; second means for blocking (9) the movement of pronation and the movement of supination, at two identical opposed “second block angles” relative to the neutral position, between the solid armature (2) relative to the horizontal support, the “second block angles” defining a “large amplitude” greater t

Abstract: The present disclosure relates to the in vivo prevention or treatment of hematologic malignancy relapse using a TNFR2 antagonist (an anti TNFR2 antagonist antibody) (i) for use in the prevention or treatment of hematologic malignancy relapse after allogeneic hematopoietic stem cell transplantation (AHCT) or after a treatment with lymphocytes and (ii) for use in enhancing the graft-versus-leukemia-activity (GVL activity) of a hematopoietic stem cell transplantation (HCT) or a treatment with lymphocytes.

Abstract: The invention concerns a method for determining, by flow cytometry, the hemoglobin F (HbF) content of each erythroid cell of a set of erythroid cells. This method applies in particular to determining the HbF content of each red blood cell of a set of red blood cells. The invention also concerns a method for determining the amount of red blood cells transfused into a patient and for monitoring the therapeutic efficacy of a treatment for sickle cell disease or ?-thalassemia.

Abstract: A method for determining at least one protein in the blood which is more precise while still being simple to implement. The method exploits in an original way the spectroscopy and the dosing techniques to determine accurately the content in proteins of the biological sample, notably for oxyhemoglobin, methemoglobin, heme bound to serum albumin and hemopexin and bilirubin. Such method can advantageously be used in various applications concerning heme-related or hemoprotein-related disorders, notably method for diagnosing, for following a treatment, for determining biomarkers or for screening. Such a method is also interesting for qualifying blood bags.

Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).

Abstract: A sensor for the continuous in-situ analysis of an aerosol flow for measuring the mass of the micron/submicron particles suspended in the air flow, including an aeraulic sorter allowing the particles to be sorted according to their size with an impactor body with a cascade of one or more stages; at least one MEMS microbalance per stage, with an oscillating silicon membrane located on the impaction zone of the particles; processor connected to each MEMS microbalance to determine the mass of all the particles on the impaction zone; a system for cleaning the MEMS microbalances allowing the evacuation of the particles from the MEMS microbalances; means for driving the aerosol flow.

Abstract: Liquid ventilator and methods integrating the concept of total liquid ventilation (TLV) using liquid volumes below functional residual capacity (FRC) of mammal's lungs are disclosed. Beyond the automatization of the whole process, the technology has been up-scaled to confirm that TLV at residual volumes below FRC can provide a safe procedure while enabling the full potential of TLV in a mammal such as humans or adult-sized animals. Such tidal liquid ventilation strongly differs from the previously known TLV approach, opening promising perspectives for a safer clinical translation. Also disclosed are apparatus and method for safe and fast induction of hypothermia during liquid ventilation of a mammal.

Abstract: The invention relates to a method for fighting fungus-growing ants, and to a formicide composition capable of destroying specifically the colonies of fungus-growing ants. The invention also relates a kit for use with said method.

Abstract: The invention relates to a computer implemented method to optimize operation of a technical system by solving deterministically a nonlinear optimization problem implying technical constraints relating to technical parameters under which the said technical system operates, the technical parameters being of a number greater than 50, characterized in that the method comprises fractal geometric partitioning of a search space into a plurality of hyperspheres as a geometrical unitary pattern and wherein the hyperspheres partitioning said search space are overlapping; calculating a quality for each hypersphere; selecting from the plurality of hyperspheres, the hypersphere with the best quality; and further comprises determining an optimum solution of the said selected hypersphere, the solution comprising values of the technical parameters to be implemented in the said technical system.

Abstract: Methods and compositions are provided that can be used to vaccinate against and treat HIV. Specifically contemplated are vaccine compositions and methods of using these compositions treat HIV in patients. Aspects of the disclosure relate to an anti-CD40 antibody-HIV antigen fusion protein comprising (i) an anti-CD40 heavy chain (HCD40)-HIV antigen (Ag) fusion protein comprising the formula: HCD40-Ag, wherein Ag is a polypeptide with at least 80% sequence identity to SEQ ID NO:1; and (ii) an anti-CD40 light chain (LCD40).